Investment analysts at William Blair issued their Q1 2026 earnings estimates for MaxCyte in a report released on Wednesday, March 12th. William Blair analyst M. Larew expects that the company will ...

MaxCyte (NASDAQ:MXCT – Free Report) had its price objective cut by Stifel Nicolaus from $11.00 to $9.00 in a report released on Wednesday morning,Benzinga reports. They currently have a buy rating on ...

MaxCyte will host a conference call today, March 11, 2025, at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived ...

MaxCyte, Inc. is rated a "Buy" due to significant upside potential despite recent share price declines. The company's core revenue is increasing and growth strategies have good prospects, driven ...

The Form 10-K filing provides investors with comprehensive information on MaxCyte’s business, including its financial statements and details about its ExPERT™ platform, a suite of products ...

MaxCyte is providing initial 2025 revenue guidance for core business revenue and SPL Program-related revenue: Core revenue is expected to grow 8% to 15% compared to 2024, inclusive of revenue from ...